Selected research
Market Structure
Global Medicines for Alzheimer Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Medicines for Alzheimer Disease Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Medicines for Alzheimer Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Medicines for Alzheimer Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Medicines for Alzheimer Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Medicines for Alzheimer Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Medicines for Alzheimer Disease Treatment include Novartis AG, AbbVie Inc, Lupin Pharmaceuticals, Inc, Janssen Global Services, LLC, H. Lundbeck A/S, F. Hoffmann-La Roche Ltd, Daiichi Sankyo Company Limited, Amneal Pharmaceuticals LLC and Actiza Pharmaceutical Private Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Medicines for Alzheimer Disease Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Medicines for Alzheimer Disease Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Medicines for Alzheimer Disease Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Medicines for Alzheimer Disease Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.
Medicines for Alzheimer Disease Treatment Segment by Company
Novartis AG
AbbVie Inc
Lupin Pharmaceuticals, Inc
Janssen Global Services, LLC
H. Lundbeck A/S
F. Hoffmann-La Roche Ltd
Daiichi Sankyo Company Limited
Amneal Pharmaceuticals LLC
Actiza Pharmaceutical Private Limited
AC Immune
Medicines for Alzheimer Disease Treatment Segment by Type
NMDA Receptor Antagonists
Cholinesterase Inhibitors
Medicines for Alzheimer Disease Treatment Segment by Application
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Medicines for Alzheimer Disease Treatment Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medicines for Alzheimer Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Medicines for Alzheimer Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medicines for Alzheimer Disease Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Medicines for Alzheimer Disease Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Medicines for Alzheimer Disease Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Medicines for Alzheimer Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Medicines for Alzheimer Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- NMDA Receptor Antagonists
- Cholinesterase Inhibitors
Applications
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Companies covered
- Novartis AG
- AbbVie Inc
- Lupin Pharmaceuticals, Inc
- Janssen Global Services, LLC
- H. Lundbeck A/S
- F. Hoffmann-La Roche Ltd
- Daiichi Sankyo Company Limited
- Amneal Pharmaceuticals LLC
- Actiza Pharmaceutical Private Limited
- AC Immune
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Medicines for Alzheimer Disease Treatment Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Medicines for Alzheimer Disease Treatment Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Medicines for Alzheimer Disease Treatment Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Medicines for Alzheimer Disease Treatment Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Medicines for Alzheimer Disease Treatment Market Dynamics
- 2.1 Medicines for Alzheimer Disease Treatment Industry Trends
- 2.2 Medicines for Alzheimer Disease Treatment Industry Drivers
- 2.3 Medicines for Alzheimer Disease Treatment Industry Opportunities and Challenges
- 2.4 Medicines for Alzheimer Disease Treatment Industry Restraints
3 Medicines for Alzheimer Disease Treatment Market by Manufacturers
- 3.1 Global Medicines for Alzheimer Disease Treatment Revenue by Manufacturers (2021-2026)
- 3.2 Global Medicines for Alzheimer Disease Treatment Sales by Manufacturers (2021-2026)
- 3.3 Global Medicines for Alzheimer Disease Treatment Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Medicines for Alzheimer Disease Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Medicines for Alzheimer Disease Treatment Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Medicines for Alzheimer Disease Treatment Manufacturers, Product Type & Application
- 3.7 Global Medicines for Alzheimer Disease Treatment Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Medicines for Alzheimer Disease Treatment Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Medicines for Alzheimer Disease Treatment Players Market Share by Revenue in 2025
- 3.8.3 2025 Medicines for Alzheimer Disease Treatment Tier 1, Tier 2, and Tier 3
4 Medicines for Alzheimer Disease Treatment Market by Type
- 4.1 Medicines for Alzheimer Disease Treatment Type Introduction
- 4.1.1 NMDA Receptor Antagonists
- 4.1.2 Cholinesterase Inhibitors
- 4.2 Global Medicines for Alzheimer Disease Treatment Sales by Type
- 4.2.1 Global Medicines for Alzheimer Disease Treatment Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Medicines for Alzheimer Disease Treatment Sales by Type (2021-2032)
- 4.2.3 Global Medicines for Alzheimer Disease Treatment Sales Market Share by Type (2021-2032)
- 4.3 Global Medicines for Alzheimer Disease Treatment Revenue by Type
- 4.3.1 Global Medicines for Alzheimer Disease Treatment Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Medicines for Alzheimer Disease Treatment Revenue by Type (2021-2032)
- 4.3.3 Global Medicines for Alzheimer Disease Treatment Revenue Market Share by Type (2021-2032)
5 Medicines for Alzheimer Disease Treatment Market by Application
- 5.1 Medicines for Alzheimer Disease Treatment Application Introduction
- 5.1.1 Hospital Pharmacy
- 5.1.2 Online Pharmacy
- 5.1.3 Retail Pharmacy
- 5.2 Global Medicines for Alzheimer Disease Treatment Sales by Application
- 5.2.1 Global Medicines for Alzheimer Disease Treatment Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Medicines for Alzheimer Disease Treatment Sales by Application (2021-2032)
- 5.2.3 Global Medicines for Alzheimer Disease Treatment Sales Market Share by Application (2021-2032)
- 5.3 Global Medicines for Alzheimer Disease Treatment Revenue by Application
- 5.3.1 Global Medicines for Alzheimer Disease Treatment Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Medicines for Alzheimer Disease Treatment Revenue by Application (2021-2032)
- 5.3.3 Global Medicines for Alzheimer Disease Treatment Revenue Market Share by Application (2021-2032)
6 Global Medicines for Alzheimer Disease Treatment Sales by Region
- 6.1 Global Medicines for Alzheimer Disease Treatment Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Medicines for Alzheimer Disease Treatment Sales by Region (2021-2032)
- 6.2.1 Global Medicines for Alzheimer Disease Treatment Sales by Region (2021-2026)
- 6.2.2 Global Medicines for Alzheimer Disease Treatment Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Medicines for Alzheimer Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Medicines for Alzheimer Disease Treatment Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Medicines for Alzheimer Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Medicines for Alzheimer Disease Treatment Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Medicines for Alzheimer Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Medicines for Alzheimer Disease Treatment Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Medicines for Alzheimer Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Medicines for Alzheimer Disease Treatment Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Medicines for Alzheimer Disease Treatment Revenue by Region
- 7.1 Global Medicines for Alzheimer Disease Treatment Revenue by Region
- 7.1.1 Global Medicines for Alzheimer Disease Treatment Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Medicines for Alzheimer Disease Treatment Revenue by Region (2021-2026)
- 7.1.3 Global Medicines for Alzheimer Disease Treatment Revenue by Region (2027-2032)
- 7.1.4 Global Medicines for Alzheimer Disease Treatment Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Medicines for Alzheimer Disease Treatment Revenue (2021-2032)
- 7.2.2 North America Medicines for Alzheimer Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Medicines for Alzheimer Disease Treatment Revenue (2021-2032)
- 7.3.2 Europe Medicines for Alzheimer Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Medicines for Alzheimer Disease Treatment Revenue (2021-2032)
- 7.4.2 Asia-Pacific Medicines for Alzheimer Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Medicines for Alzheimer Disease Treatment Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Medicines for Alzheimer Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Novartis AG
- 8.1.1 Novartis AG Company Information
- 8.1.2 Novartis AG Business Overview
- 8.1.3 Novartis AG Medicines for Alzheimer Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Novartis AG Medicines for Alzheimer Disease Treatment Product Portfolio
- 8.1.5 Novartis AG Recent Developments
- 8.2 AbbVie Inc
- 8.2.1 AbbVie Inc Company Information
- 8.2.2 AbbVie Inc Business Overview
- 8.2.3 AbbVie Inc Medicines for Alzheimer Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 AbbVie Inc Medicines for Alzheimer Disease Treatment Product Portfolio
- 8.2.5 AbbVie Inc Recent Developments
- 8.3 Lupin Pharmaceuticals, Inc
- 8.3.1 Lupin Pharmaceuticals, Inc Company Information
- 8.3.2 Lupin Pharmaceuticals, Inc Business Overview
- 8.3.3 Lupin Pharmaceuticals, Inc Medicines for Alzheimer Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Lupin Pharmaceuticals, Inc Medicines for Alzheimer Disease Treatment Product Portfolio
- 8.3.5 Lupin Pharmaceuticals, Inc Recent Developments
- 8.4 Janssen Global Services, LLC
- 8.4.1 Janssen Global Services, LLC Company Information
- 8.4.2 Janssen Global Services, LLC Business Overview
- 8.4.3 Janssen Global Services, LLC Medicines for Alzheimer Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Janssen Global Services, LLC Medicines for Alzheimer Disease Treatment Product Portfolio
- 8.4.5 Janssen Global Services, LLC Recent Developments
- 8.5 H. Lundbeck A/S
- 8.5.1 H. Lundbeck A/S Company Information
- 8.5.2 H. Lundbeck A/S Business Overview
- 8.5.3 H. Lundbeck A/S Medicines for Alzheimer Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 H. Lundbeck A/S Medicines for Alzheimer Disease Treatment Product Portfolio
- 8.5.5 H. Lundbeck A/S Recent Developments
- 8.6 F. Hoffmann-La Roche Ltd
- 8.6.1 F. Hoffmann-La Roche Ltd Company Information
- 8.6.2 F. Hoffmann-La Roche Ltd Business Overview
- 8.6.3 F. Hoffmann-La Roche Ltd Medicines for Alzheimer Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 F. Hoffmann-La Roche Ltd Medicines for Alzheimer Disease Treatment Product Portfolio
- 8.6.5 F. Hoffmann-La Roche Ltd Recent Developments
- 8.7 Daiichi Sankyo Company Limited
- 8.7.1 Daiichi Sankyo Company Limited Company Information
- 8.7.2 Daiichi Sankyo Company Limited Business Overview
- 8.7.3 Daiichi Sankyo Company Limited Medicines for Alzheimer Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Daiichi Sankyo Company Limited Medicines for Alzheimer Disease Treatment Product Portfolio
- 8.7.5 Daiichi Sankyo Company Limited Recent Developments
- 8.8 Amneal Pharmaceuticals LLC
- 8.8.1 Amneal Pharmaceuticals LLC Company Information
- 8.8.2 Amneal Pharmaceuticals LLC Business Overview
- 8.8.3 Amneal Pharmaceuticals LLC Medicines for Alzheimer Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Amneal Pharmaceuticals LLC Medicines for Alzheimer Disease Treatment Product Portfolio
- 8.8.5 Amneal Pharmaceuticals LLC Recent Developments
- 8.9 Actiza Pharmaceutical Private Limited
- 8.9.1 Actiza Pharmaceutical Private Limited Company Information
- 8.9.2 Actiza Pharmaceutical Private Limited Business Overview
- 8.9.3 Actiza Pharmaceutical Private Limited Medicines for Alzheimer Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Actiza Pharmaceutical Private Limited Medicines for Alzheimer Disease Treatment Product Portfolio
- 8.9.5 Actiza Pharmaceutical Private Limited Recent Developments
- 8.10 AC Immune
- 8.10.1 AC Immune Company Information
- 8.10.2 AC Immune Business Overview
- 8.10.3 AC Immune Medicines for Alzheimer Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 AC Immune Medicines for Alzheimer Disease Treatment Product Portfolio
- 8.10.5 AC Immune Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Medicines for Alzheimer Disease Treatment Value Chain Analysis
- 9.1.1 Medicines for Alzheimer Disease Treatment Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Medicines for Alzheimer Disease Treatment Production Mode & Process
- 9.2 Medicines for Alzheimer Disease Treatment Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Medicines for Alzheimer Disease Treatment Distributors
- 9.2.3 Medicines for Alzheimer Disease Treatment Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst